Biocept Inc logo

BIOC - Biocept Inc Share Price

$4.39 0.1  2.6%

Last Trade - 3:16pm

Micro Cap
Market Cap £41.7m
Enterprise Value £33.1m
Revenue £20.0m
Position in Universe 5560th / 6841
Unlock BIOC Revenue
Relative Strength (%)
1m -32.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -67.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.61 3.22 5.07 3.25 5.53 27.5 41.2 46.5 +114.1%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BioceptInc revenues increased from $5.5M to $27.5M. Net lossapplicable to common stockholders decreased 29% to $17.8M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Lower net loss reflects Stock-base decrease of 20% to $117K(expense), Int exp on Financial Lease Liabilitie decreaseof 9% to $228K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BIOC Revenue Unlock BIOC Revenue

Net Income

BIOC Net Income Unlock BIOC Revenue

Normalised EPS

BIOC Normalised EPS Unlock BIOC Revenue

PE Ratio Range

BIOC PE Ratio Range Unlock BIOC Revenue

Dividend Yield Range

BIOC Dividend Yield Range Unlock BIOC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BIOC EPS Forecasts Unlock BIOC Revenue
Profile Summary

Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 28, 2013
Public Since February 5, 2014
No. of Shareholders: n/a
No. of Employees: 104
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 13,402,368
Free Float (0.0%)
Eligible for
BIOC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BIOC
Upcoming Events for BIOC
Tuesday 11th May, 2021 Estimate
Q1 2021 Biocept Inc Earnings Release
Friday 30th July, 2021 Estimate
Biocept Inc Annual Shareholders Meeting
Tuesday 10th August, 2021 Estimate
Q2 2021 Biocept Inc Earnings Release
Frequently Asked Questions for Biocept Inc
What is the Biocept Inc share price?

As of 3:16pm, shares in Biocept Inc are trading at $4.39, giving the company a market capitalisation of £41.7m. This share price information is delayed by 15 minutes.

How has the Biocept Inc share price performed this year?

Shares in Biocept Inc are currently trading at $4.39 and the price has moved by 20.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biocept Inc price has moved by -19.68% over the past year.

What are the analyst and broker recommendations for Biocept Inc?

Of the analysts with advisory recommendations for Biocept Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biocept Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biocept Inc next release its financial results?

Biocept Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Biocept Inc dividend yield?

Biocept Inc does not currently pay a dividend.

Does Biocept Inc pay a dividend?

Biocept Inc does not currently pay a dividend.

When does Biocept Inc next pay dividends?

Biocept Inc does not currently pay a dividend.

How do I buy Biocept Inc shares?

To buy shares in Biocept Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biocept Inc?

Shares in Biocept Inc are currently trading at $4.39, giving the company a market capitalisation of £41.7m.

Where are Biocept Inc shares listed? Where are Biocept Inc shares listed?

Here are the trading details for Biocept Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BIOC
What kind of share is Biocept Inc?

Based on an overall assessment of its quality, value and momentum, Biocept Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biocept Inc share price forecast 2021?

Shares in Biocept Inc are currently priced at $4.39. At that level they are trading at 0.367% discount to the analyst consensus target price of 0.00.

Analysts covering Biocept Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.57 for the next financial year.

How can I tell whether the Biocept Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocept Inc. Over the past six months, the relative strength of its shares against the market has been -24.77%. At the current price of $4.39, shares in Biocept Inc are trading at -26.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biocept Inc PE Ratio?

We were not able to find PE ratio data for Biocept Inc.

Who are the key directors of Biocept Inc?

Biocept Inc's management team is headed by:

Marsha Chandler - IND
David Hale - NEC
Bruce Gerhardt - IND
Michael Nall - PRE
Ivor Royston - IND
Timothy Kennedy - CFO
Michael Terry - SVP
Samuel Riccitelli - DRC
Michael Dugan - SVP
Michael Brown - CCO
Tom Nauman - OTH
Antonio Paternostro - VPR
Brenda Tang - DMK
Gary Marchetti - OTH
Deirdre Goehler - OTH
Who are the major shareholders of Biocept Inc?

Here are the top five shareholders of Biocept Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.98% (667k shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 3.23% (432k shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 1.63% (219k shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.43% (192k shares)
Driehaus Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 0.83% (111k shares)
Similar to BIOC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.